Stockscreener 앱 받기
5.31
5.99%
0.30
시장 영업 전:
5.41
0.10
+1.88%
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara's experimental bladder cancer drug shows encouraging results - MSN
Protara Therapeutics Inc stock faces volatility amid clinical pipeline updates and biotech sector pr - AD HOC NEWS
Form 144 Protara Therapeutics For: 6 March By Investing.com - Investing.com Australia
Aug Ideas: What is the Moat Score of Protara Therapeutics IncMarket Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Sentiment Recap: Whats the profit margin of Protara Therapeutics IncGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February - MarketBeat
Equities Analysts Offer Predictions for TARA Q1 Earnings - MarketBeat
Lifesci Capital Issues Optimistic Estimate for TARA Earnings - MarketBeat
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
FY2030 Earnings Forecast for TARA Issued By HC Wainwright - MarketBeat
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN) - The Globe and Mail
Published on: 2026-03-12 04:53:12 - baoquankhu1.vn
Cowen Maintains Buy on Protara Therapeutics (TARA) March 10, 2026 - Meyka
TD Cowen reiterates Protara Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TARA Advances Clinical Programs with Key Milestones Ahead - GuruFocus
TARA Secures Financial Stability with $197.9 Million Cash Reserves - GuruFocus
Protara Therapeutics (NASDAQ:TARA) Releases Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Protara Therapeutics (NASDAQ: TARA) advances TARA-002 and IV Choline into registrational-stage trials - Stock Titan
Protara Therapeutics 2025 Annual Report: Pipeline, Regulatory Strategy, and Commercialization Plans for Cancer and Rare Disease Therapies - Minichart
Protara 10-K: Net loss $57.4M, EPS $(1.34); operating loss widens to $64.5M - TradingView
Protara Therapeutics reports $197.9M cash; Q4 net loss $17.3M, FY loss $57.4M - TradingView
Protara Therapeutics: Q4 Earnings Snapshot - marketscreener.com
TARA: TARA-002 achieved high response rates in NMIBC, with cash runway into 2028 after a major offering - TradingView
BRIEF-Protara Therapeutics Q4 EPS USD -0.37 - TradingView
Bladder cancer drug hits 68% response; Protara sees cash runway into 2028 - Stock Titan
Geopolitics Watch: What is the Moat Score of Protara Therapeutics IncWeekly Trend Recap & Verified Momentum Stock Alerts - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Millennium Management LLC Acquires Significant Stake in Protara Therapeutics Inc - GuruFocus
Broker-listed sales by 667, L.P. at TARA (NASDAQ: TARA) reported on Form 144 - Stock Titan
Protara gains as JP Morgan starts at overweight - Seeking Alpha
Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on TARA with Overweight Rating and $27 PT | TARA Stock News - GuruFocus
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
TARA SEC FilingsProtara Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Watch: Can Protara Therapeutics Inc beat the S P 5002025 Sector Review & Weekly High Return Opportunities - baoquankhu1.vn
Millennium group reports 2.76M shares in Protara (TARA) — 5.1% stake - Stock Titan
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf - Yahoo Finance
TARA PE Ratio & Valuation, Is TARA Overvalued - Intellectia AI
TARA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Protara Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
TARA Should I Buy - Intellectia AI
Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
TARA: TARA-002 advances in NMIBC and LM with promising data and expanding regulatory pathways - TradingView
667, L.P. resale reported for TARA (NASDAQ: TARA) — 26,755 shares - Stock Titan
Protara Therapeutics (TARA) Receives a Buy from Piper Sandler - The Globe and Mail
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Protara Therapeutics (TARA) to Release Earnings on Wednesday - MarketBeat
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU - MarketBeat
Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data - GuruFocus
Protara reports interim results from bladder cancer trial By Investing.com - Investing.com South Africa
Protara falls after trial data for lead asset (TARA:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Bladder phase II sinks Protara, LMs phase III wins for Palvella - BioWorld MedTech
Protara Highlights Strong Phase 2 Data for TARA-002 - TipRanks
TARA: TARA-002 shows strong efficacy and safety in NMIBC, with high CR rates and durable responses - TradingView
Protara posts positive interim ADVANCED-2 results; TARA-002 shows 68% 6‑month CR in BCG‑unresponsive NMIBC - TradingView
What's Going On With Protara Therapeutics Stock Tuesday?Protara Therapeutics (NASDAQ:TARA) - Benzinga
TARA-002 results send Protara shares upwards - The Pharma Letter
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
1.82%
자본화:
|
볼륨(24시간):